Developing new cancer drugs is expensive. Before a new cancer drug goes to trial it is developed for a year or two, and costs around $100 million. Also, 95% of cancer drugs fail in clinical trials meaning there are lots of misses before a hit. Berg, a biotech startup, wants to harness artificial intelligence to develop the next generation of cancer treatments. The company has created BPM 31510, the first cancer drug developed by artificial intelligence being tested in clinical studies. When cancer spreads mitochondria that usually tell damaged cells to die go crazy, and spread. BPM 31510 focuses on the mitochondria, and tries to restore a normal cell’s dying process. Though BPM 31510 is still in early trial stages, it could hint at how future drugs will be developed.
The next frontier in medicine: drugs designed by artificial intelligence
More of Today's Solutions
Southern Sierra Miwuk Nation regains ancestral lands near Yosemite in major c...
BY THE OPTIMIST DAILY EDITORIAL TEAM Nearly 900 acres of ancestral territory have been officially returned to the Southern Sierra Miwuk Nation, marking a ...
Read More8 fermented foods that your gut will love (and that taste great, too!)
BY THE OPTIMIST DAILY EDITORIAL TEAM Fermented foods have been a dietary staple in many cultures for centuries, but in the U.S., they’re only ...
Read MoreBreaking the silence: empowering menopausal women in the workplace
Addressing menopause in the workplace is long overdue in today's fast-changing work scene, where many are extending their careers into their 60s. According to ...
Read MoreInsect migration: the hidden superhighway of the Pyrenees
Insects, while frequently disregarded, are critical to the planet's ecosystems. They make up about 90 percent of all animal species and play important functions ...
Read More
